Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Employees

Sector

Biotechnology & Medical Research

Calendar

30/04 - Q1 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
10/25/10	4.800 $	+6.19%	14,07,584
09/25/09	4.520 $	+4.39%	17,54,980
08/25/08	4.330 $	-0.46%	10,99,539
07/25/07	4.350 $	+1.16%	9,08,729
03/25/03	4.300 $	+7.50%	7,57,113

Delayed Quote Nasdaq, July 11, 2025 at 01:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.800USD

Average target price

8.667USD

Spread / Average Target

+80.56%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 11/07/2025 am IST			5-day change	1st Jan Change
4.800 ^USD	+6.19%		+20.00%	-3.81%

26/06	Aldeyra Therapeutics, Inc. Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma	CI
26/06	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Chipmaker Optimism, Eyes Turn to Fed Leadership Speculation	MT

Capitalization	29Cr 25Cr 23Cr 21Cr 39Cr 2.46TCr 44Cr 272.88Cr 104.36Cr 1.15TCr 107.83Cr 105.6Cr 4.2TCr	P/E ratio 2025 *	-9.11x	P/E ratio 2026 *	53.3x
Enterprise value	29Cr 25Cr 23Cr 21Cr 39Cr 2.46TCr 44Cr 272.88Cr 104.36Cr 1.15TCr 107.83Cr 105.6Cr 4.2TCr	EV / Sales 2025 *	10.4x	EV / Sales 2026 *	3.7x
Free-Float	81.98%	Yield 2025 *	-	Yield 2026 *	-

Aldeyra Therapeutics, Inc. Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma	26/06	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Chipmaker Optimism, Eyes Turn to Fed Leadership Speculation	26/06	MT
Aldeyra Therapeutics Receives FDA Special Protocol Assessment Agreement for ADX-2191 Trial	26/06	MT
Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell	17/06	MT
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application For The Treatment Of Dry Eye Disease	17/06	RE
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease	17/06	CI
US FDA approves Alcon's new dry-eye drug (May 28)	29/05	RE
Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05	CI
Aldeyra Therapeutics, Inc. - Special Call	06/05
Aldeyra Therapeutics Inc Says New Drug Application Resubmission Is Anticipated Mid-2025	06/05	RE
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission	06/05	CI
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors	17/04	CI
Aldeyra Therapeutics, Inc. - Special Call	04/04

Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target	03/24/03	MT
Citigroup Adjusts Price Target on Aldeyra Therapeutics to $8 From $25, Maintains Buy Rating	17/23/17	MT
Citigroup Adjusts Aldeyra Therapeutics Price Target to $25 From $28, Maintains Buy Rating	01/23/01	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	01/22/01	MT
Oppenheimer Adjusts Aldeyra Therapeutics Price Target to $11 From $10, Maintains Outperform Rating	09/22/09	MT

Aldeyra Therapeutics, Inc. Share Price

Equities

ALDX

US01438T1060

Biotechnology & Medical Research

Valuation: Aldeyra Therapeutics, Inc.

Chart: Aldeyra Therapeutics, Inc.

Latest news: Aldeyra Therapeutics, Inc.

Last Transcript: Aldeyra Therapeutics, Inc.

Analysts' recommendations: Aldeyra Therapeutics, Inc.

Press Releases: Aldeyra Therapeutics, Inc.

News in other languages: Aldeyra Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aldeyra Therapeutics, Inc.

ETFs: Aldeyra Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma	26/06	BU
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease	17/06	BU
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference	29/05	BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX	13/05	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX	07/05	PR

USA-Les valeurs à suivre à Wall Street (actualisé)	28/23/28
Dow Jones Industrial Average : Les valeurs à suivre à Wall Street	26/19/26
USA-Les valeurs à suivre à Wall Street (actualisé)	26/19/26

1 day	+6.19%
1 week	+20.00%
Current month	+25.33%
1 month	+79.78%
3 months	+147.42%
6 months	-6.07%
Current year	-3.81%

1 week	4.12	4.92
1 month	2.6	4.92
Current year	1.14	7.2
1 year	1.14	7.2
3 years	1.14	11.97
5 years	1.14	15.95
10 years	1.14	16.7

Manager	Title	Age	Since
Todd Brady CEO	Chief Executive Officer	53	01/01/2012
Michael Alfieri DFI	Director of Finance/CFO	60	31/08/2024
Stephen Machatha PRN	Corporate Officer/Principal	48	01/01/2016

Director	Title	Age	Since
Todd Brady BRD	Director/Board Member	53	01/09/2005
Martin Joyce BRD	Director/Board Member	71	01/10/2013
Gary Phillips BRD	Director/Board Member	59	01/05/2009

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALDEYRA THERAPEUTICS, INC.	+6.19%	+20.00%	+41.18%	+6.90%	27Cr
ARGENX SE	+4.39%	+3.76%	+16.68%	+39.32%	3.33TCr
WUXI APPTEC CO., LTD.	+0.63%	-0.09%	+88.24%	-36.35%	2.78TCr
BIONTECH SE	+1.91%	+5.23%	+41.50%	-33.04%	2.75TCr
SUMMIT THERAPEUTICS INC.	+4.61%	+14.41%	+230.10%	+2,437.25%	1.84TCr
INSMED INCORPORATED	+0.20%	-1.61%	+37.56%	+289.76%	1.83TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.77%	+0.19%	+137.08%	-67.88%	1.34TCr
GENMAB A/S	+1.68%	+7.60%	-20.92%	-44.09%	1.32TCr
AKESO, INC.	-1.37%	+16.70%	+190.35%	+341.14%	1.26TCr
EXELIXIS, INC.	+2.50%	+1.96%	+103.93%	+105.22%	1.2TCr
Average	+2.00%	+4.83%	+86.57%	+303.83%	1.77TCr
Weighted average by Cap.	+1.87%	+2.98%	+80.75%	+302.76%

	2025 *	2026 *
Net sales	2.77Cr 2.37Cr 2.21Cr 2.04Cr 3.79Cr 237.58Cr 4.21Cr 26Cr 10Cr 111.33Cr 10Cr 10Cr 405.24Cr	7.76Cr 6.63Cr 6.18Cr 5.72Cr 11Cr 665.29Cr 12Cr 74Cr 28Cr 311.76Cr 29Cr 29Cr 1.13TCr
Net income	-3.17Cr -2.71Cr -2.52Cr -2.33Cr -4.33Cr -271.55Cr -4.81Cr -30Cr -12Cr -127.25Cr -12Cr -12Cr -463.19Cr	65.31L 55.8L 52.02L 48.08L 89.18L 56Cr 99.08L 6.2Cr 2.37Cr 26Cr 2.45Cr 2.4Cr 95Cr
Net Debt	-	-